XXXX and @entity10257 in combination for treating detrusor underactivity.

@entity1 @entity1421 @entity73 @entity10257
OBJECTIVE: To test the hypothesis, in a prospective randomized double-blind study, that the combination of intravesical @entity1421 ( @entity1421 ) and oral @entity10257 (BC) are additive or synergistic in improving bladder emptying, as they have been used alone for treating @entity73 with little clinical benefit. @entity1 AND METHODS: Nineteen @entity1 with detrusor underactivity (17 @entity1 and two @entity1 ) were eligible and randomized to one of two treatments. All had postvoid residual urine volumes (PVR) consistently of > 300 mL, most being reliant on clean intermittent self-catheterization (CISC). The experimental treatment group (nine @entity1 ) received once-weekly intravesical @entity1421 (1.5 mg in 20 mL 0.9% saline) plus BC 50 mg four times daily, for a total of 6 weeks. The second group of 10 @entity1 received a once-weekly instillation of saline together with placebo tablets, again for 6 weeks. RESULTS: Before treatment the median (interquartile range) PVR was 426 (405-480) mL for those receiving both drugs; this decreased to 325 (290-352) mL after completing the treatment (P < 0.015). In the placebo group the respective values were 576 (539-777) and 538 (350-775) mL (P = 0.09). Four of the @entity1 receiving the active combination reported symptomatic improvement and were able to reduce the frequency of CISC. CONCLUSION: Although there was evidence of a pharmacological effect, BC and @entity1421 had a limited therapeutic effect compared with placebo. Whilst we would not recommend this treatment as routine, it may be considered for the occasional treatment of a @entity1 with detrusor underactivity.
